

EVT801

## Chemical Properties


CAS No. : 1412453-70-3

Formula: C<sub>19</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>

Molecular Weight: 367.4

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	EVT801 is a highly selective and low-toxic VEGFR-3 inhibitor that inhibits VEGF-C-induced tumor lymphoid and angiogenesis and reduces important circulating immunosuppressive factors (CCL4, CCL5) and myeloid-derived suppressor cells (MDSC).
Targets(IC50)	ERK,VEGFR
In vitro	In HEK293 cells, EVT801 (10 nM-1 μM) dose-dependently inhibited autophosphorylation of VEGFR-1/2/3, with IC <sub>50</sub> values of 2130 nM (VEGFR-1), 260 nM (VEGFR-2), and 39 nM (VEGFR-3) [1]. In human lymphatic microvascular endothelial cells (hLMVECs), EVT801 (1 nM-1 μM) inhibited proliferation induced by VEGF-C, VEGF-D, and VEGF-A with IC <sub>50</sub> values of 15 nM, 8 nM, and 155 nM, respectively [1]. EVT801 (1 μM; 72 h) also suppressed proliferation of VEGFR-3-positive tumor cells in vitro [1].
In vivo	EVT801 (30 mg/kg; oral administration; twice daily for 7 days) has demonstrated antitumor effects in various VEGFR-3-positive mouse tumor models, including the RT-001-HAM subcutaneous patient-derived xenograft (PDX) model, the 4T1 mammary carcinoma model, the N-diethylnitrosamine-induced hepatocarcinoma model, the NCI-H1703 subcutaneous xenograft model, the Rip1-Tag2 transgenic model, and the CT26 ectopic tumor model. VEGFR-3 expression was observed in tumor-associated blood vessels in primary and metastatic kidney cancers, as well as in endothelial tumor cells. [1]

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.7218 mL	13.6091 mL	27.2183 mL
5 mM	0.5444 mL	2.7218 mL	5.4437 mL
10 mM	0.2722 mL	1.3609 mL	2.7218 mL
50 mM	0.0544 mL	0.2722 mL	0.5444 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Paillasse M R, et al. Targeting Tumor Angiogenesis with the Selective VEGFR-3 Inhibitor EVT801 in Combination with Cancer Immunotherapy[J]. Cancer Research Communications, 2022, 2(11): 1504-1519.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481